LU600082B1 - An Engineered Near-Infrared Light Responsive Exosome, and a Preparation Method and Application Thereof - Google Patents

An Engineered Near-Infrared Light Responsive Exosome, and a Preparation Method and Application Thereof

Info

Publication number
LU600082B1
LU600082B1 LU600082A LU600082A LU600082B1 LU 600082 B1 LU600082 B1 LU 600082B1 LU 600082 A LU600082 A LU 600082A LU 600082 A LU600082 A LU 600082A LU 600082 B1 LU600082 B1 LU 600082B1
Authority
LU
Luxembourg
Prior art keywords
cxcl9
cells
exosome
preparation
exo
Prior art date
Application number
LU600082A
Other languages
English (en)
Inventor
Youbo Zhao
Original Assignee
Univ Guizhou Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Guizhou Medical filed Critical Univ Guizhou Medical
Application granted granted Critical
Publication of LU600082B1 publication Critical patent/LU600082B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

. LU600082 PATENTANSPRUCHE
1. Herstellungsverfahren eines technisch hergestellten, auf Nahinfrarotlicht reagierenden Exosoms, umfassend die folgenden Schritte: Transfizieren eines rekombinanten Plasmids, das ein CXCL9-kodierendes Gen enthält, in Tumorzellen, um Zellen zu erhalten, die CXCL9 exprimieren; Inkubieren der CXCL9 exprimierenden Zellen mit Photosensibilisator nach Erhalt von ultravioletter Strahlung, um Zellkulturüberstand zu erhalten; und Trennen des Zellkulturüberstandes, um das technisch hergestellte, auf Nahinfrarotlicht reagierende Exosom zu erhalten.
2. Herstellungsverfahren nach Anspruch 1, wobei die Nukleotidsequenz des CXCL9-kodierenden Gens in SEQ ID NO.1 gezeigt ist.
3. Herstellungsverfahren nach Anspruch 1, wobei die Tumorzellen Leberkrebszellen sind.
4. Herstellungsverfahren nach Anspruch 1, wobei die Ultraviolett-Bestrahlungszeit 1 Stunde beträgt.
5. Herstellungsverfahren nach Anspruch 1, wobei der Photosensibilisator Cypat ist.
6. Herstellungsverfahren nach Anspruch 1, dadurch gekennzeichnet, dass die Trennungsbehandlung ein Verfahren von Differentialzentrifugation verwendet.
7. Technisch hergestelltes, auf Nah-Infrarot-Licht reagierendes Exosom, hergestellt durch das Herstellungsverfahren nach einem der Ansprüche 1 - 6.
8. Anwendung des technisch hergestellten, auf Nahinfrarotlicht reagierenden Exosoms nach Anspruch 7 bei der Herstellung von Arzneimitteln zur Behandlung von Leberkrebs.
9. Medikament zur Behandlung von Leberkrebs, dadurch gekennzeichnet, dass der Wirkstoff das technisch hergestellte, auf Nahinfrarotlicht reagierende Exosom nach Anspruch 7 umfasst.
10. Arzneimittel nach Anspruch 1, wobei das Medikament ferner pharmazeutisch 7600082 verträgliche Hilfsstoffe umfasst.
LU600082A 2024-12-17 2025-01-21 An Engineered Near-Infrared Light Responsive Exosome, and a Preparation Method and Application Thereof LU600082B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202411863902.8A CN119685261B (zh) 2024-12-17 2024-12-17 一种工程化近红外光响应性外泌体及其制备方法和应用

Publications (1)

Publication Number Publication Date
LU600082B1 true LU600082B1 (en) 2025-07-21

Family

ID=95038491

Family Applications (1)

Application Number Title Priority Date Filing Date
LU600082A LU600082B1 (en) 2024-12-17 2025-01-21 An Engineered Near-Infrared Light Responsive Exosome, and a Preparation Method and Application Thereof

Country Status (2)

Country Link
CN (1) CN119685261B (de)
LU (1) LU600082B1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3202783A1 (de) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Manipulierte antigen-präsentierende zellen und deren verwendung
CN112029730A (zh) * 2020-05-20 2020-12-04 深圳市芥至和生物科技有限公司 一种基因修饰的间充质干细胞及其应用
BR112023019840A2 (pt) * 2021-03-30 2023-11-07 Kainos Medicine Inc Exossomos carregados com fator 1 associado ao fas (faf1) e uso dos mesmos como agente anticâncer
CN113355290B (zh) * 2021-05-31 2022-09-13 北京理工大学 一种抗肿瘤的工程化外泌体、制备方法和应用
CN115786268A (zh) * 2021-09-10 2023-03-14 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN115261410A (zh) * 2022-07-20 2022-11-01 中山大学 一种基因编辑工程化m1型巨噬细胞外泌体的制备方法及其应用
CN117731633A (zh) * 2023-12-11 2024-03-22 浙江赛瑞欧光电有限公司 一种外泌体/光敏剂复合体及其制备方法和应用

Also Published As

Publication number Publication date
CN119685261B (zh) 2025-08-12
CN119685261A (zh) 2025-03-25

Similar Documents

Publication Publication Date Title
Luo et al. Extracellular vesicles from Akkermansia muciniphila elicit antitumor immunity against prostate cancer via modulation of CD8+ T cells and macrophages
Li et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity
CN106659742B (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
Rosenberg Immunotherapy and gene therapy of cancer
Fowler et al. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease
Tzeng et al. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy
CA2267157C (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
JP6899333B2 (ja) 汎用キラーｔ細胞
Jiang et al. Magnetic-manipulated NK cell proliferation and activation enhance immunotherapy of orthotopic liver cancer
Olivera et al. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
CN110996975A (zh) 组合癌症免疫疗法
WO2018137643A1 (zh) 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
Ding et al. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer
Riding et al. Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy
Hu et al. Genetically modified cancer vaccines: Current status and future prospects
Tu et al. FLT3L-induced virtual memory CD8 T cells engage the immune system against tumors
US10155024B2 (en) Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells
Hatami et al. Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype
CN103933558B (zh) 一种新型、广谱的治疗性肿瘤疫苗的制备和使用方法
LU600082B1 (en) An Engineered Near-Infrared Light Responsive Exosome, and a Preparation Method and Application Thereof
Coleman et al. Cytokine enhancement of immunogenicity in chronic myeloid leukaemia
WO2025152901A1 (zh) 一种用于肿瘤治疗的溶瘤病毒-t细胞嵌合体及其应用
US20210401887A1 (en) T cells from lymphatic fluid for diagnostic and therapeutic use
AU2018283319B2 (en) Materials and methods for increasing immune responses
Pfeifer Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20250721